Expert Interview
Discussing the Phase 3 results for Ardelyx' tenapanor for the control of serum phosphorus in adult patients with Chronic kidney disease undergoing dialysis
Ticker(s): ARDXInstitution: UPENN
- Associate Professor of Clinical Medicine and the Clinical Director, Glomerular Diseases Program at University of Pennsylvania.
- Currently manages 100 patients with IgAN, 1000 patients with CKD, and 15 patients with C3 glomerulopathy.
- Research focuses on Glomerular diseases, Onconephrology, and kidney biopsy.
Please describe your background and current practice setting
Added By: ben_adminHow many patients with chronic kidney disease do you currently manage?
Added By: ben_adminWhat is your current treatment algorithm for patients with chronic kidney disease?
Added By: ben_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for tenapanor?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
